Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Wolf

Showing results (31-40 of 80) with videos related to

Pageof 8
Sort By:
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|January 28, 2026
Does Smoking Influence Outcomes in Human Papillomavirus-Associated Oropharyngeal Cancer Treated with Transoral Robotic Surgery?Jane Y Tong, Vera Bzhilyanskaya, Jason K Molitoris, et al.
Leukemia & Lymphoma|April 25, 2023
Significance of the pee-value: relevance of 24-hour urine studies for patients with myelomaKelsey H Natsuhara, Chiung-Yu Huang, Jennifer Knoche, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 21, 2018
A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple MyelomaSikander Ailawadhi, Kevin R Kelly, Robert A Vescio, et al.
Transplantation and Cellular Therapy|May 27, 2023
Intensity of Cyclophosphamide-Based Bridging Therapy Before Chimeric Antigen Receptor T Cell Therapy in MyelomaAneeqa Zafar, Chiung-Yu Huang, Mimi Lo, et al.
American Journal of Clinical Pathology|January 21, 2012
20q- clonality in a case of oral sweet syndrome and myelodysplasiaKatherine Van Loon, Ryan M Gill, Patrick McMahon, et al.
British Journal of Haematology|June 15, 2005
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myelomaSundar Jagannath, Brian G M Durie, Jeffrey Wolf, et al.
Blood|May 10, 2017
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myelomaThomas Martin, Rachid Baz, Don M Benson, et al.
Integrated Environmental Assessment and Management|October 20, 2023
Reproducibility, reliability, and regulatory relevance of plant visual injury assessmentsSebastian Fellmann, Andreas Duffner, Ashlee Kirkwood, et al.
Blood Advances|September 20, 2021
Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapySwetha Kambhampati Thiruvengadam, Ying Sheng, Chiung-Yu Huang, et al.
Transplantation and Cellular Therapy|March 18, 2023
Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple MyelomaKevin R Reyes, Chiung-Yu Huang, Mimi Lo, et al.
Pageof 8

Showing results (31-40 of 80) with videos related to

Sort By:
Pageof 8
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|January 28, 2026
Does Smoking Influence Outcomes in Human Papillomavirus-Associated Oropharyngeal Cancer Treated with Transoral Robotic Surgery?Jane Y Tong, Vera Bzhilyanskaya, Jason K Molitoris, et al.
Leukemia & Lymphoma|April 25, 2023
Significance of the pee-value: relevance of 24-hour urine studies for patients with myelomaKelsey H Natsuhara, Chiung-Yu Huang, Jennifer Knoche, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 21, 2018
A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple MyelomaSikander Ailawadhi, Kevin R Kelly, Robert A Vescio, et al.
Transplantation and Cellular Therapy|May 27, 2023
Intensity of Cyclophosphamide-Based Bridging Therapy Before Chimeric Antigen Receptor T Cell Therapy in MyelomaAneeqa Zafar, Chiung-Yu Huang, Mimi Lo, et al.
American Journal of Clinical Pathology|January 21, 2012
20q- clonality in a case of oral sweet syndrome and myelodysplasiaKatherine Van Loon, Ryan M Gill, Patrick McMahon, et al.
British Journal of Haematology|June 15, 2005
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myelomaSundar Jagannath, Brian G M Durie, Jeffrey Wolf, et al.
Blood|May 10, 2017
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myelomaThomas Martin, Rachid Baz, Don M Benson, et al.
Integrated Environmental Assessment and Management|October 20, 2023
Reproducibility, reliability, and regulatory relevance of plant visual injury assessmentsSebastian Fellmann, Andreas Duffner, Ashlee Kirkwood, et al.
Blood Advances|September 20, 2021
Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapySwetha Kambhampati Thiruvengadam, Ying Sheng, Chiung-Yu Huang, et al.
Transplantation and Cellular Therapy|March 18, 2023
Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple MyelomaKevin R Reyes, Chiung-Yu Huang, Mimi Lo, et al.
Pageof 8